DAGCO Inc. trimmed its holdings in shares of CVS Health Co. (NYSE:CVS) by 27.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,059 shares of the pharmacy operator’s stock after selling 1,150 shares during the quarter. DAGCO Inc.’s holdings in CVS Health were worth $230,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Raab & Moskowitz Asset Management LLC grew its stake in CVS Health by 10.8% during the 1st quarter. Raab & Moskowitz Asset Management LLC now owns 18,718 shares of the pharmacy operator’s stock worth $1,408,000 after buying an additional 1,830 shares during the last quarter. JJJ Advisors Inc. grew its stake in CVS Health by 47.1% during the 1st quarter. JJJ Advisors Inc. now owns 1,528 shares of the pharmacy operator’s stock worth $115,000 after buying an additional 489 shares during the last quarter. BCS Wealth Management purchased a new position in CVS Health during the 1st quarter worth $200,000. WASHINGTON TRUST Co grew its stake in CVS Health by 0.3% during the 1st quarter. WASHINGTON TRUST Co now owns 216,447 shares of the pharmacy operator’s stock worth $16,283,000 after buying an additional 713 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in CVS Health by 15.1% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 1,805,793 shares of the pharmacy operator’s stock worth $137,113,000 after acquiring an additional 236,948 shares during the period. Hedge funds and other institutional investors own 74.21% of the company’s stock.

In other CVS Health news, CFO Eva C. Boratto sold 18,882 shares of the business’s stock in a transaction on Tuesday, March 16th. The shares were sold at an average price of $74.68, for a total value of $1,410,107.76. Also, Director Larry J. Merlo sold 270,650 shares of the business’s stock in a transaction dated Friday, March 26th. The stock was sold at an average price of $74.73, for a total transaction of $20,225,674.50. Following the completion of the sale, the director now directly owns 794,676 shares of the company’s stock, valued at approximately $59,386,137.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 583,892 shares of company stock valued at $43,918,083. Corporate insiders own 0.46% of the company’s stock.

CVS has been the subject of a number of research reports. Guggenheim reaffirmed a “neutral” rating on shares of CVS Health in a research report on Tuesday, March 23rd. Jefferies Financial Group raised CVS Health from a “hold” rating to a “buy” rating and set a $90.00 price target for the company in a research report on Friday, January 8th. Truist lifted their price target on CVS Health from $80.00 to $88.00 in a research report on Wednesday, April 14th. Truist Securities boosted their price objective on CVS Health from $80.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, April 20th. Finally, Morgan Stanley boosted their price objective on CVS Health from $86.00 to $92.00 and gave the company an “overweight” rating in a report on Tuesday, April 20th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $84.31.

Shares of CVS traded up $1.87 during mid-day trading on Tuesday, hitting $79.56. 330,109 shares of the company’s stock were exchanged, compared to its average volume of 6,737,496. The company has a current ratio of 0.95, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $104.33 billion, a P/E ratio of 12.84, a P/E/G ratio of 1.72 and a beta of 0.82. CVS Health Co. has a fifty-two week low of $55.36 and a fifty-two week high of $78.22. The business’s 50 day moving average is $74.98 and its two-hundred day moving average is $70.72.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Tuesday, May 4th. The pharmacy operator reported $2.04 EPS for the quarter, beating the Zacks’ consensus estimate of $1.69 by $0.35. CVS Health had a net margin of 2.99% and a return on equity of 15.60%. The firm had revenue of $69.10 billion during the quarter, compared to the consensus estimate of $68.33 billion. During the same quarter last year, the firm earned $1.91 earnings per share. The firm’s revenue was up 3.5% compared to the same quarter last year. On average, equities research analysts forecast that CVS Health Co. will post 7.43 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 3rd. Stockholders of record on Friday, April 23rd were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Thursday, April 22nd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.51%. CVS Health’s dividend payout ratio (DPR) is 28.25%.

CVS Health Company Profile

CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services.

See Also: What is the Moving Average Convergence Divergence (MACD) oscillator?

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.